ImmuCell Corp ICCC
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ICCC is a good fit for your portfolio.
News
-
ImmuCell Provides Update on Regulatory Status of Product Development Initiative for Re-Tain®
-
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
-
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2024
-
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2024
-
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2024
Trading Information
- Previous Close Price
- $4.21
- Day Range
- $4.15–4.20
- 52-Week Range
- $4.15–6.02
- Bid/Ask
- $4.18 / $4.50
- Market Cap
- $32.65 Mil
- Volume/Avg
- 5,489 / 11,500
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.52
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 80
- Website
- https://www.immucell.com
Valuation
|
Metric
|
ICCC
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.32 |
Price/Sales | 1.52 |
Price/Cash Flow | — |
Price/Earnings
ICCC
Financial Strength
|
Metric
|
ICCC
|
|---|---|
Quick Ratio | 0.87 |
Current Ratio | 2.71 |
Interest Coverage | −6.42 |
Quick Ratio
ICCC
Profitability
|
Metric
|
ICCC
|
|---|---|
Return on Assets (Normalized) | −8.94% |
Return on Equity (Normalized) | −14.95% |
Return on Invested Capital (Normalized) | −8.48% |
Return on Assets
ICCC
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Tvyynwbc | Gybcxr | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Hxxngycd | Twkgzrz | $114.2 Bil | |||
| Moderna Inc
MRNA
| Ydgdzwlkz | Cqsm | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Njqfdggbf | Phyd | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Fpkcjpfs | Dxv | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Rnvldksrt | Fpvkdz | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qsxqrmly | Wphfx | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Gjtjskx | Lsbq | $12.8 Bil | |||
| Incyte Corp
INCY
| Yvjjlxykz | Bhbhvps | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Mjpbpxdbvq | Vbjldpl | $12.2 Bil |